Categories

QBM

Newsletter

Download press release (2013-01-13)

QBM – Photo Therapeutic Medical Garment

Wearable full body skin solution

Regeneration               Medication

(Hong Kong, 2013-01-13)

Hong Kong – Quantum Bio-Medicals Ltd. announced today of the new launch of the photo therapeutic medical garment: “QBM Sunsoul” into the Hong Kong and Southern China Regional market today. This product is licensed and approved by the Canadian Health Authority (FDA equivalent) after the successful clinical trials carried out in Canada, New Zeland, Taiwan and Hong Kong. The QBM Sunsoul technology filters common light into narrow bands of photo-therapeutic wavelengths (400 nm – 450 nm range as “Blumod” and 500nm – 600 nm range as “Yelomod”).

Image1

400 nm – 450 nm range “Blumod” for Acne and Eczema

The Technology

Studies has shown that the common cause for Acne Vulgaris is Gram-Positive bacteria, especially cocci[i]. Atopic Dermatitis (Atopic Eczema) symptoms are also largely incubated by Methicillin-resistant Staphylococcus aureus (MRSA).[ii] According to a research conducted by the University of Strathclyde (U.K.), it is proven that light range of 400 nm – 450 nm is effective to kill and control Gram-positive bacteria including MRSA.[iii] Furthermore, a study conducted by the Johannes Gutenberg University (Germany) has shown this technology is proven to be extremely effective to relief Atopic Dermatitis (Atopic Eczema) symptoms with the EASI score improvement of 41% and 54% (after 3 / 6 months).[iv]

Our solution

QBM Blumod is a patent technology which allows the selective transmittance of 400 nm – 450 nm light without the health risks posed by UV (98.18% blockage of UVA and 97.78% blockage of UVB).[v] Clinical trials has confirm that there was 65% average improvement in lesion counts with 85% patients who has at least 50% average improvements by using Blumod [with at least 2 hours a week of outdoor exposure within 10AM to 4AM for 2 months in New Zealand and Australia]. It is recommended the patient is to use Blumod for at least 1-2 hours a day for 2 weeks non-stop for optimal noticeable effects.

Figure 2: Atopic Dermatitis treatment with 400nm - 450 light[vi]

Before

After

http://www.sunsoul.hk/img/cms/Blumod8.jpg

http://www.sunsoul.hk/img/cms/Blumod9.jpg

http://sunsoul.hk/img/cms/blumod%20compare%201a.jpg

http://sunsoul.hk/img/cms/blumod%20compare%201b.jpg

Figure 2: Acne Vulgaris treatment with Blumod 400nm - 450nm light[vii][viii]

Before

After

http://www.sunsoul.hk/img/cms/Blumod10.jpg

http://sunsoul.hk/img/cms/blumod%20compare%203.jpg

http://sunsoul.hk/img/cms/blumod%20compare%204a.jpg

http://sunsoul.hk/img/cms/blumod%20compare%204b.jpg

 

Figure 3: Psoriasis treatment with Blumod 400nm - 450nm light

Before

 

After

http://sunsoul.hk/img/cms/Blumod12.jpg

 

http://sunsoul.hk/img/cms/Blumod13.jpg

500 nm – 600 nm range “Blumod” for Acne and Eczema

The Technology

Vascular lesions and Pigmented lesions of skin are clinical treated successfully with 577 nm[ix] and 510 nm[x] lights. Current photo therapy treatment for these lesions are usually with laser and intense pulse light (IPL) technologies, which are very limited in the area of application.

Our solution

QBM Yelomod is a patent technology which allows the selective transmittance of 500 nm – 600 nm light without the health risks posed by UV (98.18% blockage of UVA and 97.78% blockage of UVB).[xi]  Clinical trials has confirm that there was a total of 24.7% discoloration and 21.5% overall skin quality when tested with QBM Yelomod (40mW/cm², 1hour per week for 8 weeks). QBM Yelomod does not allow IPL treatment of the patient’s skin, it also provides a supreme anti-UV barrier to avoid aging skin with up to 240.9 UPF rating (third party laboratory tested), where most other UPF50+ rated products can only pass this standard marginally.

Figure 4: Skin Improvement with Yelomod 500m – 600nm Light

Candidate 1

 

Before

After

Image12

Image13

Image14

Image15

Image16

Image17

Figure 4: Skin Improvement with Yelomod 500m – 600nm Light

Candidate 2

 

Before

After

Image18

Image19

Image20

Image21

Image22

Image23

QBM Sunsoul products’ other merits:

 

Medical Licenses and conformity certifications:

  • Patent technology: US Patent Pub. No.: 2008/01□957□
  • CE Conformity Declaration
  • Health Canada FDA: Liscence Number: 2□70
  • Intertek: ISO9001 Certiifcate Number: 488□-9
  • Intertek: ISO13485 Certificate Number: 9392□-3

 

Safety and anti-microbe certifications:

  • Taiwan Textile Research Institute: Formaldehyde test (AS/NZS CNS 11820 P3082-2007): N.D. : Report Number: TA80□013
  • Taiwan Textile Research Institute: Heavy Metal (ISO 105-E04): Lower than detection limit: Report Number: TA80□013-A
  • Taiwan Textile Research Institute: Straphylococcus Aureus Microbe test (AACC 6538): Anti-bacterial activity : 5.8: Report Number: TA90□853-B

 

UV test certifications:

  • Suncare Research Labatories LLC (US): Determination of the UV Protection Factor (UPF) for a Fabric Sample (SRL2007-89): UPF 175.63 (un-wash)263.83 (after 40 washes) [Blue]
  • Suncare Research Labatories LLC (US): Determination of the UV Protection Factor (UPF) for a Fabric Sample (SRL2007-89): UPF 147.77 (un-wash)240.91 (after 40 washes) [Yellow]
  • Taiwan Textile Research Institute: UV test (AS/NZS 4339:1996): UPF 47 (Yellow)/ UPF 59 (Blue): Report Number: TA80□013
  • Intertek: Determination of The UVR Transmission of Dry Textile (AATCC 183-2004): Percentage Blocking 98.19% (UV-A) / 97.78 (UV-B): Report Number: TWNT0057□0□0

 

About Us:

Sunsoul's revolution phototherapy garment technology is the first of its kind to selectively amplify narrow bands of healthy light from the sun and deliver them to the skin while blocking the harmful ultraviolet rays.

Our technology is developped by Dr. Michael Kriendel, a world renown expert in photo-therapy and chief technical officer of Syneron, and the benefits are both clinically proven and supported by experts around the globe.

Sunsoul is a Toronto based company, compose of a team of globally recognized scientists and dermatology specialists. Sunsoul (B.P.C.) H.K. Ltd. is the regional sole distributor for this unique technology.

Company information:

Address: Flat 1903, 23-39 Pak Tin Par Street, Tsuen Wan

Tel: 8199 0001

Fax: 2411 3892

Email:

Person of Contact

Name: Mr. Tom Lee

Title: Head of Business Development

Mobile: 63301915

Email:

 


*For security purpose, □ has been used to replace some numbers.
*To be environmental friendly, our printed press release will not include referencing section. For full referencing, please visit our website: www.qbm.hk



[i] Imamura, S., 1972, The Localization and Distribution of Gram-Positive Cocci in Normal Skin and Lesions of Acne Vulgaris. Journal of Investigative Dermatology. [PDF] Available at: <http://www.nature.com/jid/journal/v65/n2/abs/5617211a.html>[Accessed 19-01-2013]

[ii] Leung, Y.M. D., 2008. 3. The role of Staphylococcus aureus in atopic eczema. Acta Derm Venereol. [PDF] Available at: <https://www.google.com.hk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CDkQFjAA&url=http%3A%2F%2Fwww.medicaljournals.se%2Facta%2F content%2Fdownload.php%3Fdoi%3D10.2340%2F00015555-0388&ei=A2vaUKzoMemTiAeYvoHQAw&usg=AFQjCNECZudbTcsvUEylo3MtFJzBiNdlGg&bvm=bv.1355534169,d.aGc&cad=rja> [Accessed 26-12-2012]

[iii]Anderson, J., Macgregor, S.J., Maclean M., Woosley, A.G., 2008. Inactivation of Gram-Positive Bacteria. University of Strathclyde. [Patent Application] Available at: <http://www.google.com/patents/EP1924323A1?cl=en >[Accessed 27-12-2012]

[iv]Becker, D., Langer, E., Seemann, M., Seemann, G., Fell, I., Saloga, J., Grabbe, S., Stebut, E.V., 2011.  Clinical Efficacy of Blue Light Full Body Irradiation as Treatment Option for Severe Atopic Dermatitis.Department of Dermatology, University Medicine, Johannes Gutenberg University, Mainz, Germany. [PDF] Available at: < http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110790/pdf/pone.0020566.pdf> [Accessed 26-12-2012]

[v] Intertek: Determination of The UVR Transmission of Dry Textile (AATCC 183-2004): Percentage Blocking 98.19% (UV-A) / 97.78 (UV-B): Report Number: TWNT0057□0□0

[vi]Becker, D., Langer, E., Seemann, M., Seemann, G., Fell, I., Saloga, J., Grabbe, S., Stebut, E.V., 2011.  Clinical Efficacy of Blue Light Full Body Irradiation as Treatment Option for Severe Atopic Dermatitis.Department of Dermatology, University Medicine, Johannes Gutenberg University, Mainz, Germany. [PDF] Available at: < http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110790/pdf/pone.0020566.pdf> [Accessed 26-12-2012]

[vii] Chan, H.H.L., Acne treatment using selective amplification of sunlight spectrum with fluorescent therapeutic material (FTM).

[viii] Gary, M., New approach for low intensity light therapy of acne.

[ix] Gonzalez, E., Gange, R.W., Momtaz K.T., 1992. Treatment of telangiectases and other benign vascular lesions with the 577 nm pulsed dye laser: J Am Acad Dermatol. [PDF] Available at:< http://www.ncbi.nlm.nih.gov/pubmed/1430360>[Accessed 22-01-2013]

[x] Grekin, R.C., Shelton, R.M., Geisse, J.K., Frieden, I., 1993. 510-nm pigmented lesion dye laser. Its characteristics and clinical uses: J Dermatol Surg Oncol. [PDF] Available at:< http://www.ncbi.nlm.nih.gov/pubmed/8478479>[Accessed 22-01-2013]

[xi] Intertek: Determination of The UVR Transmission of Dry Textile (AATCC 183-2004): Percentage Blocking 98.19% (UV-A) / 97.78 (UV-B): Report Number: TWNT0057□0□0